Skip to main content

The Complex Physician-Patient Interaction: Expectations vs. Reality

  • Chapter
  • First Online:
The Conquest of Cancer
  • 835 Accesses

Abstract

Facing a diagnosis of cancer can be psychologically devastating. The state of mind of most patients facing a catastrophic life event evolves through five stages: denial, anger, bargaining, depression, and acceptance [635]. In the denial phase, patients’ reaction often is “this can’t be happening, not to me”, which evolves to “why me? It’s not fair” characteristic of the anger phase. Then comes the “I’ll give anything for…” of the bargaining stage, followed by the “why bother” of the depression phase, shifting to “It’s going to be OK” of the acceptance phase. In cancer patients, the latter phase is often translated into a resolute determination to “fight” and “beat” the disease, which culminates in inner peace and the acceptance of death when it becomes clear that treatment has failed. Thus, it is not surprising that most patients opt for treatment: any treatment that offers some hope. This forward-looking fighting spirit, anchored on the primeval human instinct of self-preservation, often is bolstered by a subjective understanding of information disclosed by the physician, retaining positive elements while misinterpreting or unconsciously dismissing negative ones. Hence, in the US and some Western societies where “breaking bad news” has become an accepted practice, the physician must provide hope and emotional healing throughout the disclosure process. This can be accomplished by ensuring that the patient is ready to assimilate bad news, that information provided meets the patient’s wants, needs and preferences, and that the emotional impact of bad news is mitigated or retrieved by emphasizing whatever positive aspects of the case. Factors that can affect the patient’s understanding benefits and risks of treatment should be taken into account. They include the disclosure venue and timing (hospital, office, and context settings); the content of the disclosure (thoroughness, clarity, and specificity); and the level of personal interest and empathy conveyed by the physician [636]. Only then should the Oncologist formulate a management plan, taking into account the biological, psychological, behavioral, and social aspects of the patient’s disease and his/her input [637, 638]. The founder of the Schwartz Center movingly described his own experience with lung cancer only days before his death to illustrate the enormous power of caregivers’ empathy on a patient’s frame of mind [639].

Some see a hopeless end, while others see an endless hope.

Unknown

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Faguet G. Pain Control and Drug Policy. Op. cit.

    Google Scholar 

  2. Kübler-Ross E. On death and dying: What the dying have to teach doctors, nurses, clergy, and their own families. New York, NY, Touchstone, 1997.

    Google Scholar 

  3. Loge JH, Kaasa S, Hytten K. Disclosing the cancer diagnosis: the patients’ experiences. Eur J Cancer 1997;33:878–882.

    Article  CAS  PubMed  Google Scholar 

  4. Jenkins V, Fallowfield L, Saul J. Information needs of patients with cancer: results from a large study in UK cancer centers. Br J Cancer 2001;84:48–51.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Parker PA, Baile WF, de Moor C, et al. Breaking bad news about cancer patients’ preferences for communications. J Clin Oncol 2001;19:2049–2056.

    CAS  PubMed  Google Scholar 

  6. Schwartz K. A patient’s story. The Boston Globe, July 16, 1995. Web 23 Jul. 2013. http://www.theschwartzcenter.org/docs/patient_story.pdf

  7. Bruera E, Neumann CM, Mazzocato C, et al. Attitudes and beliefs of palliative care physicians regarding communication s with terminally ill cancer patients. Palliat Med 2000;14:287–298.

    Article  CAS  PubMed  Google Scholar 

  8. Fallowfield LJ, Jenkins VA, Beveridge HA. Truth may hurt but deceit hurts more: communication in palliative care. Palliat Med 2002;16:297–302.

    Article  CAS  PubMed  Google Scholar 

  9. Kaplowitz SA, Campo S, Chiu WT. Cancer patients’ desires for communication of prognosis information. Health Commun 2002;14:221–41.

    Article  PubMed  Google Scholar 

  10. Faguet GB. The War on Cancer. Op. cit.

    Google Scholar 

  11. Slevin ML, Stubbs L, Plant HJ, et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ 1990;300:1458–1460.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Carlsson M. Cancer patients seeking information from sources outside the health care system. Support Care Cancer 2000;8:453–457.

    CAS  PubMed  Google Scholar 

  13. Cassileth BR, Zupkis RV, Sutton-Smith K, et al. Information and participation preferences among cancer patients. Ann Intern Med 1980;92:832–836.

    Article  CAS  PubMed  Google Scholar 

  14. Gattellari M, Butow PN, Tattersall MH. Informed consent: what did the doctor say? Lancet 1999;353:1713.

    Article  CAS  PubMed  Google Scholar 

  15. Kübler-Ross E. Op. cit.

    Google Scholar 

  16. Coulter A. Partnerships with patients: the pros and cons of shared clinical decision making. J Health Service Res Policy 1997;2:112–121.

    CAS  Google Scholar 

  17. Charles C, Whelam T, Gafni A. What do we mean by partnership in making decisions about treatment? BMJ 1999;319:780–782.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Degner LF, Krsitjanson LJ, Bowman D, et al. Information needs and decisional preferences in women with breast cancer. JAMA 1997;277:1485–1492.

    Article  CAS  PubMed  Google Scholar 

  19. Institute of Medicine. Crossing the quality chasm: a new health system for the 21st century. Washington, DC: National Academies Press; 2001.

    Google Scholar 

  20. Hewitt M, Simone JV (Ed) Ensuring quality cancer care. National Cancer Policy Board. Institute of Medicine and Commission On Life Sciences. National Research Council:. Washington, DC, National Academy Press, 1999.

    Google Scholar 

  21. Schnider EC, Epstein AM. Developing a System to Assess the Quality of Cancer Care: ASCO’s National Initiative on Cancer Care Quality (table 2). JCO 2004;22:2985–2991.

    Article  Google Scholar 

  22. Quality Oncology Practice Initiative: Summary of measures Spring 2013. Web 28 Jul. 2013. http://qopi.asco.org/Documents/QOPISpring13MeasuresSummary_001.pdf

  23. NCCN Clinical Practice Guidelines in Oncology. Web 17 Aug. 2013. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp

  24. Faguet GB. Pain Control and Drug Policy.

    Google Scholar 

  25. NCI’s simplified informed consent: Recommendations. Web 29 Jul. 2013. http://www.cancer.gov/clinicaltrials/conducting/simplification-of-informed-consent-docs/page2

  26. World Medical Association declaration of Helsinki. Web 28 Jul. 2013. http://history.nih.gov/research/downloads/helsinki.pdf

  27. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report. Washington, DC: DHEW Publication No. 0578–0012, 1978. Web 2 Aug. 2013. http://www.hhs.gov/ohrp/humansubjects/guidance/belmont.html

  28. Permissible Medical Experiments. Trials of War Criminals before the Nuremberg Military Tribunals under Control Council Law No. 10: Nuremberg October 1946–April 1949. Washington DC, U.S. Government Printing Office (n.d.), vol. 2, pp. 181–182.

    Google Scholar 

  29. Owen E. Time Daily Center for Disease Control and Prevention. U.S. Pubic Health Service Syphilis Study at Tuskegee: Presidential Apology, May 16, 1997. Web 2 Aug. 2013. http://www.cdc.gov/tuskegee/clintonp.htm

  30. DOE Openness: Human Radiation Experiments: ACHRE Report. Chapter 5: The Manhattan district Experiments; the first injection. Washington, D.C., Superintendent of Documents U.S. Government Printing Office, June 1998. Web 2 Aug. 2013. http://www.hss.energy.gov/healthsafety/ohre/roadmap/achre/chap5_2.html

  31. Eyal, Nir, Informed Consent, The Stanford Encyclopedia of Philosophy (Fall 2012 Edition), Edward N. Zalta (ed.). Web 3 Aug. 2013. http://plato.stanford.edu/entries/informed-consent/

  32. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. Op. cit.

    Google Scholar 

  33. Hewlett S. Consent to clinical trials: preliminary study of the views of prospective participants. J Med Ethics 1996;22:232–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  34. Evans M. Justified deception? The single blind placebo in drug research. J Med Ethics 2000;26:188–93.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Leighl N, Gattleari M, Butow P, et al. Discussing adjuvant cancer therapy. J Clin Oncol 2001;19:1768–1778.

    CAS  PubMed  Google Scholar 

  36. Yardley SJ, Davis CL, Sheldon F. Receiving a diagnosis of lung cancer: patients’ interpretations, perceptions and perspectives. Palliat Med 2001, 15:379–86.

    Article  CAS  PubMed  Google Scholar 

  37. Wolf SM, Paradise J, Caga-Anan C. The Law of Incidental Findings in Human Subjects Research: Establishing Researchers’ Duties. J Law Med Ethics 2008;36:361–383.

    Article  PubMed Central  PubMed  Google Scholar 

  38. Gottlieb S. FDA censures NEJM editor. BMJ 2000;320:1562.

    Article  PubMed Central  PubMed  Google Scholar 

  39. Crewdson J. Op. cit.

    Google Scholar 

  40. Cook-Deegan RM. Do research moratoria work? National Bioethic Advisory Commission. Cloning human beings. Vol II, Commissionned Papers. Rockville, MD. 1997.

    Google Scholar 

  41. Editorial. Retraction. J Clin Oncol 2001. Op. cit.

    Google Scholar 

  42. Habeck M. Clinical research comes under scrutiny. Lancer Oncol 2001 Oct 2 (10):588.

    Google Scholar 

  43. SSKRP attorneys in the news. Class action suit against Fred Hutchinson Cancer Center sends shock waves through clinical trials community. Web 3 Aug. 2013. http://www.sskrplaw.com/lawyer-attorney-1478109.html

  44. Faguet GB. The War on Cancer. Op. cit.

    Google Scholar 

  45. Zier LS, Burack JH, Mico G, et al. Surrogate Decision Makers’ Responses to Physicians’ Predictions of Medical Futility. Chest 2009;136:110–117.

    Article  PubMed Central  PubMed  Google Scholar 

  46. Gabbay E, Calvo-Broce J, Meyer KB, et al. The Empirical Basis for Determinations of Medical Futility. J Gen Intern Med 2010;25:1083–1089.

    Article  PubMed Central  PubMed  Google Scholar 

  47. Chastek B, Harley C, Kallich J, et al. Health Care Costs for Patients With Cancer at the End of Life. JOP 2012;8:75s–80s.

    Google Scholar 

  48. Morden NE, Chang CH, Jacobson JO, et al. End-Of-Life care for Medicare Beneficiaries with cancer is highly intensive overall and varies widely. Health Aff 2012;31:786–796.

    Article  Google Scholar 

  49. Blackhall LJ. Must we always use CPR? N Engl J Med 1987;317:1281–1285.

    Article  CAS  PubMed  Google Scholar 

  50. Paris JJ, Crone RK, Reardon F. Physicians’ refusal of requested treatment. N Engl J Med 1990;322:1012–1015.

    Article  CAS  PubMed  Google Scholar 

  51. Goldberg GR, Meier DE. A Swinging Pendulum: Comment on “On Patient Autonomy and Physician Responsibility in End-of-Life Care” Arch Intern Med 2011;171:854. doi:10.1001/archinternmed.2011.173

  52. Leadbetter R. Danaus. Encyclopedia Mythica. Web 8 Aug. 2013. http://www.pantheon.org/articles/d/danaus.html

  53. AMA Code of Medical Ethics: Opinion 2.037 – Medical Futility in End-of-Life Care. Web 8 Aug. 2013. http://www.ama-assn.org/ama/pub/physician-resources/medical-ethics/code-medical-ethics/opinion2037.page

  54. Caplan AL. Odds and ends: trust and the debate over medical futility. Ann Intern Med 1996;125:688–689.

    Article  CAS  PubMed  Google Scholar 

  55. Scneiderman LJ, Jecker NS, Jonsen AR. Medical futility: its meaning and ethical implications. Ann Intern Med 1990;112:949–954.

    Article  Google Scholar 

  56. Caplan AL. Op. cit.

    Google Scholar 

  57. Schneiderman LJ, Jecker NS, Jonsen AR. Medical futility: Response to critics. Ann Inter Med 1996;125:669–674.

    Article  CAS  Google Scholar 

  58. Berry DA, Broadwater G, Klein JP, et al. High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2002;20:743–750.

    Article  CAS  PubMed  Google Scholar 

  59. Transplant Data by Center Report, Breast cancer, Number of Transplants Reported for Breast cancer From 2008 – 2011. Web 15 May 2013. http://bloodcell.transplant.hrsa.gov/research/transplant_data/us_tx_data/data_by_disease/national.aspx

  60. Powles TJ, Coombes RC, Smith IE, et al. Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet 1980;1:580–582.

    Article  CAS  PubMed  Google Scholar 

  61. Breathnach O, Freidlin B, Conley B, et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 2000;19:1734–1742.

    Google Scholar 

  62. Berry DA, Broadwater G, Klein JP, et al. Op. cit.

    Google Scholar 

  63. Mettu NB, Hurwitz H, Hsu DS. Use of Molecular Biomarkers to Inform Adjuvant Therapy for Colon Cancer. Oncology 2013;27:746–54. Web 20 Sept. 2013. http://www.cancernetwork.com/colorectal-cancer/content/article/10165/2152538?cid=intraarticle

  64. Van Loon K, Venook AP. Biomarkers in Colon Cancer: The Chasm Between Expectations and Reality. Oncology 2013 Vol 27 No. 8. Web 20 Sept. 2013. http://www.cancernetwork.com/colorectal-cancer/content/article/10165/2152548

  65. Califano, JA Jr., Physician-Assisted Living, America, November 14, 1998, pp. 10–12.

    Google Scholar 

  66. UNESCO: The Routes of Santiago de Compostela in France, available online at http://whc.unesco.org/sites/868-loc.htm

  67. Saunders C. The evolution of hospices. Free inquiry. Winter 1991/92:19–23.

    Google Scholar 

  68. A controlled trial to improve care for seriously ill hospitalized patients. The Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments (SUPPORT). The SUPPORT Principal Investigators. JAMA 1995;274:1591–1598.

    Google Scholar 

  69. Califano, JA Jr. Op. cit.

    Google Scholar 

  70. World Health Organization. Cancer pain relief and palliative care. Geneva, Switzerland: World Health Organization; 1990:11–12.

    Google Scholar 

  71. Clinical Practice Guidelines: Statement on Clinical Practice Guidelines for Quality Palliative Care. American Academy of Hospice and Palliative Medicine June 2006. Web 11 Sept. 2013. http://www.aahpm.org/Practice/default/quality.html

  72. United States Senate Special Committee on Aging: Death with Dignity: A inquiry into related public issues, Part 1. Web 11 Sept. 2013. http://www.aging.senate.gov/publications/871972.pdf

  73. Ibidem.

    Google Scholar 

  74. Saunders CM. The Management of Terminal Illness. London: Hospital Medicine Publications; 1967.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Faguet, G. (2015). The Complex Physician-Patient Interaction: Expectations vs. Reality. In: The Conquest of Cancer. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-9165-6_12

Download citation

Publish with us

Policies and ethics